Global Splenomegaly Therapeutics Market 2019-2023
SKU ID : TNV-14032403 | Publishing Date : 13-Mar-2019 | No. of pages : 116
Detailed TOC of Global Splenomegaly Therapeutics Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Drug therapy - Market size and forecast 2018-2023
• Vaccination - Market size and forecast 2018-2023
• Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TYPE
• Congestive splenomegaly
• Infiltrative splenomegaly
• Neoplastic splenomegaly
• Immune splenomegaly
PART 10: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• GlaxoSmithKline plc
• Incyte Corporation
• Merck & Co., Inc.
• Novartis AG
• Sanofi
PART 16: APPENDIX
• Research methodology
• List of abbreviations
PART 17: EXPLORE TECHNAVIO
Exhibit 01: Global rare diseases therapeutics market
Exhibit 02: Segments of global rare diseases therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for reduction in spleen size
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Drug therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: JAKAVI/JAKAFI sales in $ millions
Exhibit 22: Drug therapy - Year-over-year growth 2019-2023 (%)
Exhibit 23: Vaccination - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Vaccination - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by product
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: GlaxoSmithKline plc - Vendor overview
Exhibit 46: GlaxoSmithKline plc - Business segments
Exhibit 47: GlaxoSmithKline plc - Organizational developments
Exhibit 48: GlaxoSmithKline plc - Geographic focus
Exhibit 49: GlaxoSmithKline plc - Segment focus
Exhibit 50: GlaxoSmithKline plc - Key offerings
Exhibit 51: Incyte Corporation - Vendor overview
Exhibit 52: Incyte Corporation - Business segments
Exhibit 53: Incyte Corporation - Organizational developments
Exhibit 54: Incyte Corporation - Key offerings
Exhibit 55: Merck & Co., Inc. - Vendor overview
Exhibit 56: Merck & Co., Inc. - Business segments
Exhibit 57: Merck & Co., Inc. - Organizational developments
Exhibit 58: Merck & Co., Inc. - Geographic focus
Exhibit 59: Merck & Co., Inc. - Segment focus
Exhibit 60: Merck & Co., Inc. - Key offerings
Exhibit 61: Novartis AG - Vendor overview
Exhibit 62: Novartis AG - Business segments
Exhibit 63: Novartis AG - Organizational developments
Exhibit 64: Novartis AG - Geographic focus
Exhibit 65: Novartis AG - Segment focus
Exhibit 66: Novartis AG - Key offerings
Exhibit 67: Sanofi - Vendor overview
Exhibit 68: Sanofi - Business segments
Exhibit 69: Sanofi - Organizational developments
Exhibit 70: Sanofi - Geographic focus
Exhibit 71: Sanofi - Segment focus
Exhibit 72: Sanofi - Key offerings
Exhibit 73: Validation techniques employed for market sizing
Keyplayers in Global Splenomegaly Therapeutics Market 2019-2023
GlaxoSmithKline plcIncyte Corporation
Merck & Co., Inc.
Novartis AG
Sanofi